Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Precaution Statements to Be Revised for Ketoprofen-Based OTC Drugs
November 1, 2010
- Takeda Sets Up Global Business Development Organization
November 1, 2010
- PMDA to Have Fewer Active Officials Dispatched from Korosho
November 1, 2010
- Daiichi Sankyo Healthcare Voluntarily Recalls Skin Cream
November 1, 2010
- PhRMA to Include Its Demand in US-Japan Talks for Regulatory Reform
October 25, 2010
- NICE Recommends Aricept for Mild AD
October 25, 2010
- Applications for Accreditation of Foreign Manufacturers Simplified
October 25, 2010
- Large Differences in Participation in Multinational Clinical Trials
October 25, 2010
- NDA Review Period Shortening in Japan: Mr Narita
October 25, 2010
- Indacaterol Significantly Improves Breathlessness: Novartis
October 25, 2010
- Korosho Requires Revisions of Package Inserts for Topical Ketoprofen
October 25, 2010
- 1st Gov't-Industry Meeting Held to Ensure Stable Supply of Mo-99
October 25, 2010
- Sales of Ethical Drugs Up 2.5% in August: Crecon Report
October 25, 2010
- Eli Lilly Japan to Target Orthopedic Surgeons in Promoting Forteo
October 25, 2010
- Continued Sales of Ketoprofen Products Should Be Permitted: CDFS
October 25, 2010
- Allermist Improves Ophthalmic Allergic Symptoms: Prof. Kurono
October 25, 2010
- CSO Market to Grow at 14.4% in FY2010 and Onward: MIC Research
October 25, 2010
- Original Itraconazole Product Shows Inter-Lot Differences
October 25, 2010
- 2 Kohdo-iryo Recommended for Use under Health Insurance Programs
October 25, 2010
- Price Settlement Rate 17.9% as of September at NPhA Members
October 25, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…